A B S T R A C T The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order a) to define when in pregnancy resistance to the pressor effects of angiotensin II develops; b) to define the physiologic sequence of events leading to this resistance; and c) to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy-induced hypertension.
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With this prospective approach, two separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy.
192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy-induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy, (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy-induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the two groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the two groups became significant (P < 0.01) by [23] [24] [25] [26] wk of pregnancy.
Among patients requiring more than 8 ng/kg/min on
INTRODUCTION
Normal human pregnancy, compared to the nonpregnant state, is characterized by increased plasma renin concentration, renin activity, renin substrate, angiotensin II (A-II),' and aldosterone (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Elevated excretory and secretory rates of aldosterone also have been observed in normal pregnancy (12) (13) (14) (15) (16) (17) (18) . Normal pregnant women are also known to be quite resistant to the pressor effects of infused A-II (19, 20) . In contrast, pregnancies complicated by pregnancy-induced hypertension are associated wtih lowered levels of plasma renin concentration (21, 22) , and plasma and urinary aldosterone (9, (13) (14) (15) . Additionally, patients with pregnancy-induced hypertension are exquisitely sensitive to the pressor effects of A-II (20, 23) , when compared to normotensive pregnant women. The results of these studies confirm the findings of Abdul-Karim and Assali (19) that normal-term pregnant subjects are resistant to the pressor effects of injected A-II. The results of this study also show that the onset of this resistance occurs early and is maintained throughout pregnancy. However, at 30 wk of pregnancy in subjects who remain normal, a slight and continuing decrease in resistance to A-II is noted when compared to that resistance observed between 18-30 wk pregnancy.
In those subjects who developed pregnancy-induced hypertension, the observations of Chesley (20) were confirmed, in that the subjects of this study with pregnancyinduced hypertension were exquisitely sensitive to infused A-II. Of pregnancy, the maximal resistance to A-IT was observed, (14.9±1.1 ng/kg/min). From 18 wk pregnancy until approximately 30 wk, the pressor response remained markedly blunted, the mean dose ranging between 13.5-15.0 ng/kg/min. After 30 wk there was the beginning of a small but continually decreasing resistance to A-II. The dose requirement fell to a mean of 10.7+0.71 ng/ kg/min at 38 wk of pregnancy. The number of tests, the dose requirements, means, and SEM are shown according to weeks of pregnancy in Table II. 72 of the subjects studied developed pregnancy-induced hypertension and one developed eclampsia. For the purpose of this study, pregnancy-induced hypertension is defined as a) the acute development of hypertension in a woman whose blood pressure was normal in the early stages of pregnancy and at 6 wk postpartum and, b) the persistent elevation of blood pressure to at least 140/90, which must have represented an increase in the diastolic pressure of not less than 20 mm Hg above previous pregnancy levels. Eclampsia is defined as the superimposition of grand mal seizures upon the above definition of hypertension.
Early in pregnancy, these 72 women also became very resistant to the pressor effects of infused A-II, just like those who remained normal. As graphically illustrated in Fig. 2 , this resistance became maximal at 15-18 wk of pregnancy, the dose required being 12.9±1.1 ng/kg/min. However, from this early period of pregnancy forward, the resistance progressively decreased as pregnancy advanced. The difference between the pressor dose requirements of those subjects who remained normal and of those destined to develop pregnancy-induced hypertension was apparent by 22 wk and became highly significant (P less than 0.01) by 23-26 wk. The difference between the groups became progressively widened thereafter. Even though both groups were clinically normal at 27-38 wk pregnancy, the difference in responsiveness to A-II was marked (P less than 0.001) as shown in Fig. 2 . The early difference between the two groups of patients (Fig. 2 ) at 14 wk pregnancy can not at present be explained. The number of tests, dose requirements, and ment of proteinuria was a late and inconsistant feature confined to women who had already become hypertensive. There was no laboratory evidence in any of these subjects of impaired renal function. Even during the acute phase of hypertension, no patient had plasma urea nitrogen values above 12 mg%.
Four subjects who later developed hypertension remained resistant to angiotensin, that is they required more than 8 ng/kg/min of A-II to elicit a pressor response throughout pregnancy. Such a pattern has been observed previously in two primigravid patients with chronic hypertension. Only longer follow-up of these four patients may reveal whether they too are suffering from chronic hypertension rather than pregancy-induced hypertension. One patient has been followed through two pregnancies. The results in this subject, J. D. R., are shown in Tables VI and VII.V During her first pregnancy, the patient became sensitive to A-II, requiring less than 8 ng/ kg/min, by the 31st wk of pregnancy, and this sensitivity persisted (Table VII) . Through wk 35, the patient was normotensive, without edema or proteinuria. 6 (10) . Several mechanisms have been postulated previously that would account for an increase in the release of renin by the juxtaglomerular apparatus of the maternal kidney early in pregnancy. These mechanisms include, a) the natriuretic effect of progesterone, b) the relaxing effect of progesterone on vascular smooth muscle, and c) the "shunting" of blood to the pelvic viscera. Coincident with the increase in angiotensin substrate as a result of the hyperestrogenic state of early pregnancy (7), an evident increase in A-II would then obtain. These changes, resulting in increased plasma A-II in early pregnancy, would create a physiologic state with respect to pressor responsiveness analogous to that whch Kaplan and Silah proposed for the resistance to A-II in nonpregnant subjects with high plasma renin activity (24) . This hypothesis has found confirmation in the measurements of A-II levels in the plasma by Chinn and Diisterdieck (25) .
That these systems, renin-angiotensin II-aldosterone, are operative at increased levels in early pregnancy is suggested by the findings of Scott, who has shown that plasma volume begins to increase in pregnancy as early as 6-8 wk pregnancy and rises progressively thereafter until approximately 28-30 wk of pregnancy, when the maximum plasma volume expansion is usually reached (26) . It is interesting to note from the present study that in those gravidas who remained normotensive throughout pregnancy, a slight but continuing decrease in resistance to A-II pressor effects began at approximately 30 wk pregnancy, the same time that plasma volume reaches its maximal expansion. These corollaries may suggest that in normal pregnancy there is relative physiologic underfilling until approximately 30 wk pregnancy. It should be emphasized, however, that even after maximal vollume expansion has occurred and a slight decrease in resistance is observed, normal gravidas remain markedly resistant to the pressor effects of A-II throughout the remainder of pregnancy. This would suggest that factors other than relative volume deficits may represent the principal determinants of A-II pressor responsiveness in pregnancy.
Alternative explanations for the early acquisition of angiontensin resistance in pregnant subjects may be attributable to the appearance of angiotensinase in these women. However, while controversy exists concerning the presence of increased angiotensinase in late pregnancy, Berger and Langhans (27) [23] [24] [25] [26] wk, while clinically normal, they became clearly defined as a separate group. At this early stage of gestation many of these subjects had become exquisitely sensitive to A-II in spite of the fact that they exhibited no clinical stigmata of pregnancy-induced hypertension (Fig. 2 . Tables IV and V) . Therefore, in this group of subjects destined to develop hypertension, the declining resistance to the pressor effects of A-II occurred considerably before the time of expected maximal volume expansion and long before the development of hypertension. While the mechanism of decreasing resistance to A-II in this group of subjects is not defined by this study, the corollaries cited above would favor the proposition that the principal determinant was a decreased refractoriness of the arterioles of these subjects to A-II. Ames, Borkowski, Sicinski, and Laragh have reported an increasing vascular sensitivity with prolonged infusion of A-II in normal men (31) . In this context, pregnancy-induced hypertension may represent a failure of physiologic adaptation to A-II that occurs in the vessels of those gravidas who remain normotensive. Under this circumstance, the production of renin by the uterus (32, 33) , if it is physiologically active in pregnancy (34) , and if its production is not subject to the same control mechanisms as that of renal origin (35, 36) , would jeopardize to pregnancy-induced hypertension those gravidas who failed to develop or maintain vascular refractoriness during pregnancy.
The marked differences between the two groups of subjects by the 28th wk of pregnancy at a time when both groups are clinically normal, that is, normotensive and without edema or proteinuria, suggests that a screening test at the beginning of the third trimester is feasible. Of the 120 subjects who remained normal, 103 had at least one infusion of A-II between the 28th and 32nd wk; 87% of them were resistant, in that they required more than 8 ng/kg/min to elicit the pressor response in every study during that time (Table VI) . That is, 87% of these young primigravid, predominantly Black, high-risk subjects did not develop hypertension. 6 On the other hand, of the 72 subjects who ultimately developed pregnancy-induced hypertension, 50 were studied at least once during the 28-32nd-wk time period. 45 (90%) had at least one study in which the pressor dose was less than 8 ng/kg/min in each case.
During the 28-32nd-wk time period, 46 of the subjects who remained normotensive had two or more tests. Only one subject required less than 8 ng/kg/min (5 and 7) in each study. During this same gestational time, 33 subjects who ultimately developed hypertension were studied on two or more occasions. Only one of these subjects required more than 8 ng/kg/min on each of the pressor tests and in this subject in all three tests thereafter, the dose requirement was less than 8 ng/kg/min.
If we consider these data, it is reasonable to assume that a high degree of predictability of the ultimate development of pregnancy-induced hypertension might be achieved with good pregnancy dating and if two or more tests were performed during the 28-32nd-wk period of time. It may be possible that the ability to predict continued normalcy may approach 100%; the normals by definition being a homogeneous group that manifest early and continued vascular resistance to A-II. However, it is entirely possible that better predictability may not be possible within the group that develops hypertension than was achieved by this study. McCartney, for example, observed that the clinical diagnosis of preeclampsia when compared to renal biopsies in the same patients was confirmed in only 44 of 62 primigravid pregnancies (71%), while the remaining pregnancy biopsies revealed 15 patients to have chronic renal disease (24%) and three patients to have normal biopsies (5%) (37) . Certainly any clinical grouping of pregnancy-induced hypertension, even when restricted to young primigravid patients, will include an admixture of patients with labile hypertension or chronic renal disease.
The concept of a pressor substance being used to identify the patient at risk of developing pregnancyinduced hypertension is not new. Dieckman and Michel 6 In this group of 103 who remained normal, 161 studies were performed between wk 28 and 32. A dose of more than 8 ng/kg/min was required in 147 studies; [6] [7] [8] ng/kg/ min in 9 studies and less than 6 ng/kg/min in 5 instances. (38) described an increased vascular sensitivity to posterior pituitary extracts in women with pregnancyinduced hypertension. Raab, Schroeder, Wagner, and Gigie (39), employing infusions of epinephrine and norepinephrine in a prospective study, demonstrated an increased vascular sensitivity to the pressor effects of these catecholamines in 17 of 100 women. However, only 10 of 17 women later developed pregnancy-induced hypertension; and of these 10, only 3 patients were primigravidas. In addition, the diagnostic criterion required to identify these patients was an increase in systolic blood pressure of greater than 60 mm Hg. This marked increase in blood pressure seems much too dangerous to be accepted at present.
The technique described in this report, utilizing A-II infusions is safe and appears to be highly selective. It also offers the possibility of patient selection for prospective studies of pregnancy-induced hypertension at a time when clinically evident disease and the ensuing physiologic and/or pathophysiologic consequences of the disease are not present. These late consequences may represent sequelae that may obscure the search for the etiology. Additionally, this technique offers a method for the early selection of patients who will receive close observation and form the basis for a group in which various treatment and preventive modalities may be evaluated.
